In order to identify men who are most suitable for prostate biopsy, there is a need to identify a group at risk, not just of prostate cancer, but of significant prostate cancer.
— National Collaborating Centre for Cancer Funding (Funded to produce guidelines for the NHS by NICE)
The Mitomic™ Prostate Test from MDNA is the most accurate way of determining if a patient is at risk of having clinically significant prostate cancer, outperforming every other test on the market with just a simple blood test. Its high negative predictive value for clinically significant cancer enables more accurate and informed biopsy decisions.
176 million women worldwide suffer from endometriosis, a disease that is notoriously difficult to diagnose
The Mitomic™ Endometriosis Test (MET™) is for use in females of child-bearing age to improve the early detection of the disease and accelerate the time to first medical intervention. MET is the first ever non-invasive blood-based test for endometriosis, with the potential to significantly reduce the diagnostic delay and stall disease progression with earlier intervention.
Almost every prostate cancer patient will survive for 5 years or more if it is diagnosed at stage 1 or 2
— Cancer Research UK
The Mitomic Prostate Core Test is a highly accurate, proprietary test that uses existing prostate biopsy tissue to determine the presence of malignant cells. A prostate cancer biopsy samples just a small fraction of the prostate gland, potentially missing the tumor and contributing to a high false negative rate – even in second biopsies. By detecting underlying molecular alterations in normal appearing tissue the Mitomic Prostate Core Test can provide a more accurate reliable result, quickly and easily with a simple lab test.
At MDNA Life Sciences we’re constantly working on bringing new, highly accurate tests to market for hard to diagnose diseases. Mitomic® Tests are currently in development for the early detection of Ovarian, Lung, Cervical, Uterine and Breast cancers.